Please note that the content of this book primarily consists of
articles available from Wikipedia or other free sources online.
Tercica, Inc., is a biopharmaceutical company based in Brisbane,
California, USA. It is owned by Ipsen. It is the current developer
of Increlex (mecasermin rDNA origin] injection), also known as
recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica
has applied to the Food and Drug Administration (FDA) for approval
of Increlex as a long-term therapy for growth failure in children
with severe primary IGF-1 deficiency (Primary IGFD), which is
characterized by growth faiulre, and as a treatment for children
with growth hormone (GH) gene deletion who have developed
neutralizing antibodies to growth hormone. Tercica licensed rights
to develop, manufacture, and market Increlex from Genentech, Inc.
Increlex is currently in Phase III clinical trials to evaluate the
safety and efficacy of Increlex in children with Primary IGFD.
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!